Companies › OX2 Therapeutics
1 active drug program in 7 registered trials: 4 Phase 1, 1 Phase 4, 1 Phase 3, 1 Phase 2; Genitourinary, Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Imiquimod Toll-like receptor 7 agonist | TLR7 | Phase 1 | Diffuse Midline Glioma, H3 K27M-Mutant; HSIL, High-Grade Squamous Intraepithelial Lesions; Basal Cell Carcinoma; Cervical Carcinoma … | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06356012 | Imiquimod | Phase 4 | HSIL, High-Grade Squamous Intraepithelial Lesions | Genitourinary | Dec 2026 |
| NCT06305910 | Imiquimod | Phase 1 | Diffuse Midline Glioma, H3 K27M-Mutant | Oncology | Jan 2027 |
| NCT06305910 | Imiquimod | Phase 1 | Diffuse Midline Glioma, H3 K27M-Mutant | Oncology | Jan 2027 |
| NCT07210775 | Imiquimod | Phase 1 | Oral Dysplasia | Oncology | Oct 2027 |
| NCT06686043 | Imiquimod | Phase 2 | Cervical Carcinoma | Oncology | Aug 2028 |
| NCT07251413 | Imiquimod | Phase 1 | Cutaneous Basal Cell Carcinoma | Oncology | Dec 2028 |
| NCT05212246 | Imiquimod | Phase 3 | Basal Cell Carcinoma | Oncology | Oct 2032 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.